Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 2Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 127Lung Neoplasms 51Triple Negative Breast Neoplasms 35Breast Neoplasms 34Small Cell Lung Carcinoma 30Ovarian Neoplasms 27Squamous Cell Carcinoma of Head and Neck 25Neoplasm Metastasis 21Fallopian Tube Neoplasms 20Endometrial Neoplasms 20Neoplasms 17Parkinson Disease 4, Autosomal Dominant Lewy Body 15Head and Neck Neoplasms 13Colorectal Neoplasms 11Carcinoma 11Prostatic Neoplasms 9Oropharyngeal Neoplasms 9Esophageal Neoplasms 9Urinary Bladder Neoplasms 8Carcinoma, Transitional Cell 8Pancreatic Neoplasms 7Carcinoma, Squamous Cell 7Lung Diseases 6Laryngeal Neoplasms 6Carcinoma, Ovarian Epithelial 6Adenocarcinoma of Lung 6Uterine Cervical Neoplasms 5Respiratory Tract Neoplasms 5Mouth Neoplasms 5Mesothelioma 5

Interventions

Cisplatin 15Gemcitabine 14durvalumab 10pembrolizumab 7Oxaliplatin 6Bevacizumab 6Capecitabine 5lenvatinib 4Nivolumab 4S 1 (combination) 3Liquid Biopsy 3Irinotecan 3Folfox protocol 3Fluorouracil 3Carboplatin 3zanidatamab 2tremelimumab 2envafolimab 2Trastuzumab 2Leucovorin 2Injections 2Blood Specimen Collection 2Albumin-Bound Paclitaxel 2trastuzumab deruxtecan 1toripalimab 1tislelizumab 1poly ICLC 1niraparib 1neratinib 1larotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Carboplatin × 90 days × Clear all
NCT04956640 2026-05-29

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Eli Lilly and Company

Phase 1/2 Active not recruiting
540 enrolled
GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05771480 2026-04-21

TOURMALINE

AstraZeneca

Phase 3 Active not recruiting
142 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

AstraZeneca

Phase 2 Recruiting
454 enrolled
GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡